Sirnaomics Ltd. (SEHK: 2257)
Health Care · Biotechnology · US
HK$3.80
+1.34% today · -70.1% 1Y
Sirnaomics Ltd. (SEHK: 2257) operates in the Biotechnology industry within the Health Care sector. The company is valued at $52.66M and employs 37 people.
Over the last twelve months the share price has lost 70.1%, trading between 3.55 and 13.43.
Tweenvest scores Sirnaomics Ltd. across four factors: quality 25/100, value 74/100. Its strongest factor is value.
2257 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $52.66M
- Revenue (TTM)
- $32.00K
- P/E
- —
- EPS
- -0.11
- Dividend yield
- —
- Beta (5Y)
- -0.06
- 52-week high
- HK$13.43
- 52-week low
- HK$3.55
- Avg volume (3M)
- —
- Shares outstanding
- 108.90M
- Employees
- 37
- Next earnings
- —
About Sirnaomics Ltd.
Sirnaomics Ltd. is an RNA therapeutics biopharmaceutical company, founded in 2007 and headquartered in Gaithersburg, Maryland. The company is dedicated to identifying and developing innovative therapeutic compounds aimed at addressing significant medical needs across the United States and the People's Republic of China. Its leading pipeline assets include STP705, which is being investigated for conditions such as cutaneous squamous cell carcinoma in situ, basal cell carcinoma, various liver-related cancers (cholangiocarcinoma, hepatocellular carcinoma, liver metastases), as well as for keloid scar remodeling, hypertrophic scarring, and fat sculpting. Another prominent candidate, STP707, is designed to treat cholangiocarcinoma, hepatocellular carcinoma, liver metastases, metastatic cutaneous squamous cell carcinoma, non-small cell lung cancer, and both liver and lung fibrosis. Beyond these lead programs, Sirnaomics is advancing STP355 for a range of cancers; STP369 for head and neck/bladder cancers; STP779 for liver, lung, and pancreatic cancers; and STP902 for breast cancer. The company's portfolio also extends to infectious diseases with STP702 for influenza, STP908 for COVID-19, the RIM730 COVID-19 vaccine, and STP909 for HPV/cervical cancer. Furthermore, its developmental pipeline encompasses STP122G for thrombotic disorders, STP125G for hypertriglyceridemia, STP144G for complement-mediated ailments, STP133G for cardiometabolic conditions, and STP155G for hepatitis B virus.
- ISIN
- KYG2050P1028
- Founded
- 2007
- Listed since
- Dec 30, 2021
- Exchange
- The Stock Exchange of Hong Kong Ltd.
- Currency
- HKD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Gain Therapeutics, Inc.NasdaqGM: GANX | $54.99M | $1.26 | -23.17% |
| Adocia SAENXTPA: ADOC | $53.73M | €2.40 | -1.32% |
| Helix BioPharma Corp.TSX: HBP | $52.92M | CA$0.98 | +6.52% |
| OSE Immunotherapeutics SAENXTPA: OSE | $52.78M | €2.00 | -1.86% |
| UBI Pharma Inc.UNQ: 6562 | $52.10M | NT$— | — |
| CG Invites Co., Ltd.KOSDAQ: A083790 | $52.02M | ₩902.00 | -3.01% |
| CellSeed Inc.TSE: 7776 | $51.50M | ¥206.00 | -2.37% |
| RenovoRx, Inc.NasdaqCM: RNXT | $51.45M | $1.14 | -10.94% |
Figures last refreshed Oct 18, 2026.